Screener
GeneDx Holdings WGS Operating Income
Discontinued — last reported Q1 '26
Operating Income at other companies
Other financials
Where this comes from
Reported directly by GeneDx Holdings in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: GeneDx Holdings’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001818331-26-000041
| Line item | Three months ended March 31, 2026 | 2025 |
|---|---|---|
| Research and development | 19,804 | 12,577 |
| Selling, general and administrative | 74,591 | 50,450 |
| Impairment loss | 31,287 | — |
| Loss from operations | (57,471) | (4,551) |
| Non-operating (expenses) income, net | ||
| Change in fair value of financial liabilities | 2,540 | (1,100) |
| Interest expense, net | (717) | (640) |
| Loss on extinguishment of debt | (6,565) | — |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is GeneDx Holdings's operating income?
- GeneDx Holdings (WGS) reported operating income of -$57.47M in Q1 2026.
- How has GeneDx Holdings's operating income changed year-over-year?
- GeneDx Holdings's operating income decreased by 1162.8% year-over-year, from -$4.55M to -$57.47M.
- What is the long-term trend for GeneDx Holdings's operating income?
- Over 3 years (2021 to 2025), GeneDx Holdings's operating income has grown at a -69.2% compound annual growth rate (CAGR), from -$446.15M to -$13.08M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about GeneDx Holdings's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude